Conditions: Advanced Cancer Advanced Solid Tumors
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 45
Healthy volunteers: no

Brief summary:
The study is being conducted to determine the maximum tolerated dose, overall safety and tolerability profile, and pharmacokinetic profile of CP-751,871 and sunitinib when given in combination with advanced solid tumors.

Detailed description:
The study was closed to enrollment on 14 Jan 2011 and terminated secondary to excessive screen failure rate and for business reasons associated with Pfizer's business decision to stop development of the figitumumab compound. Safety concerns did not contribute to the decision to terminate this clinical trial.

Arms:
arm 1: Escalating cohorts of CP-751,871 + Sunitinib

Interventions: intervention 1: CP-751,871 intervention 2: Sunitinib
Intervention descriptions: intervention 1: CP-751,871 IV, every 3 weeks intervention 2: Sunitinib - daily dosing

Protocol document: